Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1991 2
1992 1
1994 2
1995 2
1999 2
2004 2
2006 2
2008 1
2009 1
2010 2
2011 2
2012 4
2013 1
2014 5
2015 7
2016 7
2017 7
2018 7
2019 7
2020 6
2021 8
2022 9
2023 9
2024 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
Kashizaki F, Chen H, Miyasaka A, Tsuchiya N, Yamada C, Okazaki S, Kaneko M, Kano T, Kameda Y, Kikuchi A, Yumoto K, Osawa H, Koizumi H, Takahashi K, Kaneko T. Kashizaki F, et al. Among authors: miyasaka a. Clin Lung Cancer. 2024 Jan;25(1):e52-e57.e2. doi: 10.1016/j.cllc.2023.09.009. Epub 2023 Oct 5. Clin Lung Cancer. 2024. PMID: 37932180
Lactulose: A treatment for hyperammonemia in a lysinuric protein-intolerant patient with dynamic blood amino acid concentrations.
Kakisaka K, Sato T, Wada Y, Ito A, Eto H, Abe H, Kanazawa J, Yusa K, Kooka Y, Endo K, Yoshida Y, Oikawa T, Kuroda H, Miyasaka A, Akasaka M, Matsumoto T. Kakisaka K, et al. Among authors: miyasaka a. Mol Genet Metab Rep. 2022 Jul 15;32:100898. doi: 10.1016/j.ymgmr.2022.100898. eCollection 2022 Sep. Mol Genet Metab Rep. 2022. PMID: 35865266 Free PMC article. No abstract available.
Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K, Oda K, Ikeda Y, Sone K, Miyasaka A, Kashiyama T, Fukuda T, Uehara Y, Arimoto T, Kuramoto H, Wada-Hiraike O, Kawana K, Yano T, Osuga Y, Fujii T. Inaba K, et al. Among authors: miyasaka a. Gynecol Oncol. 2015 Aug;138(2):323-31. doi: 10.1016/j.ygyno.2015.05.031. Epub 2015 May 29. Gynecol Oncol. 2015. PMID: 26033306
Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer.
Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, Miyasaka A, Kashiyama T, Arimoto T, Kuramoto H, Kawana K, Yano T, Osuga Y, Fujii T. Chuwa AH, et al. Among authors: miyasaka a. Gynecol Oncol. 2016 Jun;141(3):564-569. doi: 10.1016/j.ygyno.2016.04.003. Epub 2016 Apr 16. Gynecol Oncol. 2016. PMID: 27079211
103 results